Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC 50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity In Vitro Werner syndrome RecQ helicase-IN-3 (example 96) (0-10 µM; 8-20 days) shows antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: SW48, DLD1 WRN-KO cells Concentration: 0-10 µM Incubation Time: 8-20 days Result: Showed antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. In Vivo Werner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) shows anticancer activity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) Dosage: 120 mg/kg Administration: P.o.; daily for 22 days Result: Inhibited tumor growth. Form:Solid IC50& Target:IC 50 : 0.06 µM (WRN)